Examination of the Pancreas in New-onset Diabetes

Diabetes Mellitus Clinical Trial

— EXPAND  

Official title:

Examination of the Pancreas in New-onset Diabetes (EXPAND Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02001337
• Other study ID #: 10-006868
• Status: Completed
• Start date: May 2013
• Est. completion date: November 30, 2016

Study information

• Verified date: November 2019
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and then screen this cohort for pancreatic cancer

Description:

Compared to the general population, subjects >50 years of age with new-onset diabetes (DM) are 8-times more likely to have pancreatic cancer (PaC). The likelihood of PaC in new-onset DM is further increased in those who have weight loss or elevated CA19-9. In this study patients with newly diagnosed diabetes will be prospectively identified. Those with weight loss and/or elevated pancreatic cancer marker (CA 19-9) will undergo pancreatic imaging. All subjects will be followed up to 24 months. If successful in identifying surgically removable PaC, this study will fundamentally change our practice and will be a major breakthrough in PaC treatment and research.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: November 30, 2016
• Est. primary completion date: November 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Patient Characteristics:

--Suspected or definite new-onset diabetes based on recent blood sugar and hemoglobin A1c values

• No acute illness or steroid therapy

• No prior pancreas surgery

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Other:
• medical chart review
baseline, quarterly follow-up for 24 months
• survey administration
baseline
• Specimen collection
baseline

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.	We will prospectively identify patients with newly diagnosed diabetes and perform pancreatic imaging to identify pancreatic cancer	Follow subjects for 2 years.

External Links

•   Mayo Clinic Clinical Trials